MORPHINE SULFATE | N022195 | HIKMA PHARMACEUTICALS USA INC
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Citizen Petition from Lannett Company, Inc. FDA-2016-P-1650 · 6 docket documents Lannett Company, Inc. filed this petition requesting that the FDA Commissioner assign a therapeutic equivalence rating of AA to Morphine Sulfate Oral Solution, 100 mg/5 mL (NDA 201517), approved June 23, 2011, under section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act. Lannett also requests | Other | 2016-06-15 | Withdrawn | Lannett Company, Inc. |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$0.4847
per ml
Lowest NADAC/Unit
$0.0444
per ml
Brand NDCs
0
Generic NDCs
7
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 00054051741MORPHINE SULF 100 MG/5 ML CONC | $0.4847 | ML | Generic | — | 2026-06-17 |
| 00054051744MORPHINE SULF 100 MG/5 ML CONC | $0.4185 | ML | Generic | — | 2026-06-17 |
| 00054051750MORPHINE SULF 100 MG/5 ML CONC | $0.3280 | ML | Generic | — | 2026-06-17 |
| 00054023849MORPHINE SULF 20 MG/5 ML SOLN | $0.1206 | ML | Generic | — | 2026-06-17 |
| 00054023749MORPHINE SULF 10 MG/5 ML SOLN | $0.0888 | ML | Generic | — | 2026-06-17 |
| 00054023863MORPHINE SULF 20 MG/5 ML SOLN | $0.0682 | ML | Generic | — | 2025-07-23 |
| 00054023763MORPHINE SULF 10 MG/5 ML SOLN | $0.0444 | ML | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.